perindopril actavis 5 mg
actavis group ptc ehf., island - perindopril - 58 - hypotensiva
bortezomib actavis 3,5 mg
actavis group ptc ehf., island - bortezomib - 44 - cytostatica
irbesartan actavis 150 mg
actavis group ptc ehf., island - irbesartan - 58 - hypotensiva
irbesartan actavis 300 mg
actavis group ptc ehf., island - irbesartan - 58 - hypotensiva
glidipion (previously pioglitazone actavis group)
actavis group ptc ehf - pioglitazón hydrochlorid - diabetes mellitus, typ 2 - lieky používané pri cukrovke - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone je tiež uvedené, pre kombináciu s inzulínu v typu 2 diabetes mellitus dospelých pacientov s nedostatočnou glykemický kontroly na inzulínu, pre ktorých je metformín je nevhodné, pretože kontraindikácii alebo neznášanlivosti. po začatí liečby s pioglitazone, pacienti by mali byť preskúmané po 3 až 6 mesiacov na posúdenie primeranosti odpoveď na liečbu (e. zníženie hba1c). u pacientov, ktorí nedokážu zobraziť primeranú odpoveď, pioglitazone by mali byť ukončené. z hľadiska potenciálnych rizík s dlhodobou liečbou, prescribers by mal potvrdiť na následné bežné recenzie, ktoré v prospech pioglitazone je zachovaná.
rapilysin
actavis group ptc ehf - retepláza - infarkt myokardu - antitrombotické činidlá - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
abricef
actavis group ptc ehf., island - cefotaxím - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
sindaxel
actavis group ptc ehf. - paklitaxel - 44 - cytostatica
sindronat 400 mg
actavis group ptc ehf. - kyselina klodrónová - 87 - varia i
flutasin 250 mg
actavis group ptc ehf. - flutamid - 44 - cytostatica